Your browser doesn't support javascript.
loading
Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson's disease.
Gomes, Sara; Garrido, Alicia; Tonelli, Francesca; Obiang, Donina; Tolosa, Eduardo; Martí, Maria José; Ruiz-Martínez, Javier; Vinagre-Aragón, Ana; Hernandez-Eguiazu, Haizea; Croitoru, Ioana; Marshall, Vicky L; Koenig, Theresa; Hotzy, Christoph; Hsieh, Frank; Sakalosh, Marianna; Tengstrand, Elizabeth; Padmanabhan, Shalini; Merchant, Kalpana; Bruecke, Christof; Pirker, Walter; Zimprich, Alexander; Sammler, Esther.
Afiliação
  • Gomes S; Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, DD1 5EH, UK.
  • Garrido A; Parkinson's Disease and Movement Disorders Unit, Institut Clínic de Neurociències, Hospital Clinic Universitari, Barcelona, Spain.
  • Tonelli F; Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Obiang D; Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, DD1 5EH, UK.
  • Tolosa E; Parkinson's Disease and Movement Disorders Unit, Institut Clínic de Neurociències, Hospital Clinic Universitari, Barcelona, Spain.
  • Martí MJ; Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Ruiz-Martínez J; Parkinson's Disease and Movement Disorders Unit, Institut Clínic de Neurociències, Hospital Clinic Universitari, Barcelona, Spain.
  • Vinagre-Aragón A; Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Hernandez-Eguiazu H; Parkinson's Disease and Movement Disorders Unit, Institut Clínic de Neurociències, Hospital Clinic Universitari, Barcelona, Spain.
  • Croitoru I; Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Marshall VL; Department of Clinical and Experimental Neurology, Laboratory of Parkinson disease and other Neurodegenerative Movement Disorders (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Koenig T; Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Hotzy C; Hospital Universitario Donostia, San Sebastián, Spain.
  • Hsieh F; Group of Neurodegenerative Diseases, Biodonostia Research Institute, San Sebastián, Spain.
  • Sakalosh M; Hospital Universitario Donostia, San Sebastián, Spain.
  • Tengstrand E; Group of Neurodegenerative Diseases, Biodonostia Research Institute, San Sebastián, Spain.
  • Padmanabhan S; Group of Neurodegenerative Diseases, Biodonostia Research Institute, San Sebastián, Spain.
  • Merchant K; Hospital Universitario Donostia, San Sebastián, Spain.
  • Bruecke C; Group of Neurodegenerative Diseases, Biodonostia Research Institute, San Sebastián, Spain.
  • Pirker W; Neurology, Queen Elizabeth University Hospital, Institute of Neurological Sciences, Glasgow, UK.
  • Zimprich A; Department of Neurology, Medical University of Vienna, Wien, Austria.
  • Sammler E; Department of Neurology, Medical University of Vienna, Wien, Austria.
NPJ Parkinsons Dis ; 9(1): 52, 2023 Apr 04.
Article em En | MEDLINE | ID: mdl-37015928
ABSTRACT
Elevated urine bis(monoacylglycerol)phosphate (BMP) levels have been found in gain-of-kinase function LRRK2 G2019S mutation carriers. Here, we have expanded urine BMP analysis to other Parkinson's disease (PD) associated mutations and found them to be consistently elevated in carriers of LRRK2 G2019S and R1441G/C as well as VPS35 D620N mutations. Urine BMP levels are promising biomarkers for patient stratification and potentially target engagement in clinical trials of emerging targeted PD therapies.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article